Silence Therapeutics plc (SLN) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value

Silence Therapeutics plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value

Silence Therapeutics plc (SLN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $6.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-05

• Silence Therapeutics plc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $6.80M, a 0.00% change from fiscal 2024.
• Silence Therapeutics plc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $6.80M, a 195.65% increase from fiscal 2023.
• Silence Therapeutics plc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $2.30M, a 360.00% increase from fiscal 2022.
• Silence Therapeutics plc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $500.00K.